Abou-Alfa GK et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21(6):796-807. Abstract
Abou-Alfa GK et al. Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. ASCO 2021;Abstract 4086.
Abou-Alfa GK et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Gastrointestinal Cancers Symposium 2022;Abstract 379.
Cheng A-L et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract
Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2. Gastrointestinal Cancers Symposium 2022;Abstract 423.
Javle M et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021;6(10):803-15. Abstract
Kelley RK et al. Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. ESMO Asia Virtual Oncology Week 2021;Abstract VP10-2021.
Kelley RK et al. Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. Gastrointestinal Cancers Symposium 2022;Abstract TPS669.
Oh D-Y et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Gastrointestinal Cancers Symposium 2022;Abstract 378.
Yoo C et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational multicenter retrospective study. Liver Cancer 2021;10(2):107-14. Abstract
Zhu AX et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarlDHy trial. JAMA Oncol 2021;7(11):1669-77. Abstract